Neuropsychobiology
2023
Matti Gärtner, Anne Weigand, Christian Keicher et al.
Cognition and emotion are fundamentally integrated in the brain and mutually contribute to behavior. The relation between working memory (WM) and emotion is particularly suited to investigate cognition-emotion interaction since WM is an essential component of many higher cognitive functions. Ketamine affects not only WM but also has a profound impact on emotional processing. Effects of acute...
Advances in experimental medicine and biology
2023
Angelos Halaris, John Cook
The glutamatergic system is the primary excitatory pathway within the CNS and is responsible for cognition, memory, learning, emotion, and mood. Because of its significant importance in widespread nervous system function, it is tightly regulated through multiple mechanisms, such as glutamate recycling, microglial interactions, and inflammatory pathways. Imbalance within the glutamatergic system...
Journal of medical economics
2023
Maryia Zhdanava, Amanda Teeple, Dominic Pilon et al.
To describe real-world esketamine nasal spray access and use as well as healthcare resource use (HRU) and costs among adults with evidence of major depressive disorder (MDD) with suicidal ideation or behavior (MDSI). Adults with ≥1 claim for esketamine nasal spray and evidence of MDSI 12 months before/on the date of esketamine initiation (index date) were selected from Clarivate's Real World...
Revista da Associação Médica Brasileira
2023
Idevaldo Floriano, Antônio Silvinato, Wanderley Marques Bernardo
The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field to standardize how to conduct, and to assist in the reasoning and decision-making of doctors. The information provided by this project must be critically evaluated by the physician responsible for the conduct that will be adopted, depending on the conditions and the...
International journal of general medicine
2023
Lin-Lin Liu, Jing-Hui Hu, Jing-Jing Pan et al.
Depressive symptoms are common among perimenopausal women with breast cancer having modified radical mastectomy. Esketamine exerts antidepressant effects. This study aims to assess whether an intraoperative sub-anesthetic dose of esketamine prevents postoperative depressive symptoms in these patients. In this randomized, triple-blinded, placebo-controlled trial, we will enroll 130...
Yakugaku Zasshi
2023
Satoshi Deyama
Ketamine, an N-methyl-D-aspartate receptor antagonist, elicits swift antidepressant effects even in subjects with treatment-resistant depression. Nonetheless, owing to the serious adverse effects associated with ketamine, including psychotomimetic effects, the development of safer rapid-acting antidepressants is imperative. The elucidation of the mechanisms underlying the antidepressant effects...
Biologie aujourd'hui
2023
Jean-Philippe Guilloux, Thi Mai Loan Nguyen, Alain M. Gardier
Ketamine, a non-competitive antagonist of the N-methyl-D-aspartate-glutamate receptor (R-NMDA), has a rapid (from 24 h post-dose) and prolonged (up to one week) antidepressant effect in treatment resistant depression and in rodent models of anxiety/depression. Arguments regarding its cellular and molecular mechanisms underlying its antidepressant activity mainly come from animal studies....
Biologie aujourd'hui
2023
Philippe Fossati
Thirty percent of depressed patients are treatment resistant (TRD) suggesting the need of new therapeutic strategy. Recently, it has been shown that ketamine, an anesthetic agent with dissociative effects, has potent and rapid antidepressant properties. Ketamine is a ionotropic glutamatergic NMDA antagonist that inhibits gabaergic neurons. Its antidepressant effect peaks at 24 h post-treatment....
Biologie aujourd'hui
2023
Emilie Olié, Aiste Lengvenyte, Philippe Courtet
In France, suicidal behaviors remain a major public health issue. Depressed patients with suicidal ideation have more severe depressive symptoms, a more unfavorable disease course, and a greater number of suicide attempts than patients without suicidal ideation. Unfortunately, conventional antidepressants tend to be less effective in patients with suicidal tendencies than in those without....
Egyptian Pharmaceutical Journal
2023
Gehan S. Georgy, Amany M Gad, H. Anwar et al.
Background The pupae of mulberry silkworms, family Bombycidae, possess a great number of proteins that cover all of the necessary amino acids obligatory for well-being. Objective In this study, we aimed to evaluate the probable antipsychotic effect of pupae of mulberry silkworms in a rat model of schizophrenia prompted by ketamine on the cerebral cortex, hippocampus, and striatum, the brain...
Medicine Science | International Medical Journal
2023
Guven Akcay
Schizophrenia is a serious neuropsychiatric disorder that affects 1% of the world's population. It plays an important role in psychiatric symptoms, including major depression and schizophrenia. However, it is also known that one of the main reasons underlying the pathogenesis of schizophrenia is oxidative stress. Transcranial direct current stimulation (tDCS) has recently been a promising...
Progress in Brain Research
2023
Kenji Hashimoto
Neuroinflammation plays a key role in the pathogenesis of major depressive disorder (MDD), including treatment-resistant depression (TRD). Patients with TRD have higher levels of inflammatory biomarkers compared with responders to antidepressants. Multiple lines of evidence suggest that the gut-microbiota-brain axis via the vagus nerve plays a key role in neuroinflammation. Preclinical and...
Frontiers in Psychiatry
2023
Emily Whinkin, Therry Rose J Eparwa, Michelle C Julseth et al.
Assess changes in symptoms of anxiety, depression, and psychosocial or spiritual distress before and after ketamine-assisted psychotherapy (KAP) in individuals with problematic substance use (PSU). A retrospective chart review was performed on participant data from two five-year prospective outcomes studies: the AIMS Medical Outcomes Study (AMOS) and the AIMS Cancer Outcomes Study (ACOS). The...
Frontiers in Psychiatry
2023
Alexander Kaltenboeck, Elisa Foerster, Sabrina Strafner et al.
A 28-year-old man was admitted to our psychiatric ward with severe obsessive-compulsive disorder (OCD) and comorbid depression. At intake, obsessive-compulsive symptoms were present most time of the day and were related to an intense fear of causing interpersonal misunderstandings. Various treatment attempts, including cognitive-behavioural therapy (CBT) with exposure and response prevention...
Fear Extinction
2023
Olga Y. Ponomareva, Robert J. Fenster, Kerry J. Ressler
Extinction is the process by which the memory of a learned conditioned association decreases over time and with introduction of new associations. It is a vital part of fear learning, and it is critical to recovery in multiple fear-related disorders, including Specific and Social Phobias, Panic Disorder, Obsessive Compulsive Disorder (OCD), and Posttraumatic Stress Disorder (PTSD). The process...
Journal of Behavioral and Brain Science
2023
Melissa C. Selinger, David M. Compton, Hamilton Morris et al.
3 citations
The management of patients with concomitant chronic pain (CP) and Major Depressive Disorder (MDD) remains challenging for clinicians. Current chronic pharmacologic management is often unsuccessful, or has intolerable side effects to the patients. While not restricted to patients with chronic pain, these patients are often diagnosed with depression, presenting with symptoms such as poor mood,...
Frontiers in Psychiatry
2023
Shanthi Sarma, Arulmathy Arunachalam, Memunatu Kamara et al.
6 citations
The following paper described two cases of patients with catatonic depression in bipolar disorder (BD) referred to our electroconvulsive therapy (ECT) service. Both were deemed not medically fit for ECT, and were, instead, treated with intravenous (IV) ketamine. Both responded with a resolution of symptoms, returning to baseline level of functioning. During the COVID-19 pandemic, given the...
Therapeutic Advances in Psychopharmacology
2023
Farhan Fancy, Sipan Haikazian, Danica E. Johnson et al.
23 citations
Background: The therapeutic potential of subanesthetic doses of ketamine appears promising in unipolar depression; however, its effectiveness in treating bipolar depression (BD) remains uncertain. Objective: This systematic review aimed to summarize findings on the use of ketamine for the treatment of BD by assessing its efficacy, safety, and tolerability. Design: Systematic review. Methods: We...
AIMS Public Health
2023
Aderonke Oyetunji, C. Blanco Huelga, Kailee Bunte et al.
9 citations
Depression and suicidality are significant challenges faced by cancer patients, particularly those in advanced stages of the disease or nearing the end of life. Conventional antidepressant therapies often have limited effectiveness or delayed onset of action, making the exploration of alternative treatments crucial. The use of ketamine as a potential treatment for depression and suicidality in...
Industrial Psychiatry Journal
2023
Pradhyuman Chaudhary, Prathmesh Shah, Prakash Mehta
4 citations
ABSTRACT Background: Depression is often a debilitating and recurrent psychiatric disorder. Depression with suicidal ideation, being a psychiatric emergency, often needs intensive intervention such as Electro-Convulsive Therapy (ECT). ECT may be refused because of stigma and perceived risk. Intravenous ketamine therapy, being an alternative to ECT for quick response compared to routine...